- US appeals court rejects Bayer’s argument in weedkiller case
- Decision is setback to strategy to get Supreme Court review
In an opinion Monday, the 11th US Circuit Court of Appeals rejected the German company’s argument that federal law on pesticide labels trumps state court claims from plaintiffs who say Roundup should come with a cancer warning.
The decision makes it harder for Bayer to overcome thousands of outstanding lawsuits that are complicating new Chief Executive Officer
Bayer’s shares fell as much as 1.7% in early trading Tuesday, bringing their decline over the past 12 months to 52%. They were up 0.5% to €28.72 ($30.82) at 3:30 p.m. in Frankfurt.
Setback to Strategy
The ruling is a setback to Bayer’s hopes that the US Supreme Court will
Read More:
Bayer still has an appeal pending before the 3rd Circuit, where it is similarly arguing that federal law preempts state-based claims. The argument is based on the Environmental Protection Agency’s finding that glyphosate, Roundup’s active ingredient, isn’t a carcinogen and the fact that the EPA approved the Roundup label without a warning.
Bayer disagrees with the 11th Circuit decision, the company said in a statement, arguing that it contradicts Supreme Court precedent and Congress’s “objective of uniformity in pesticide labeling.” Bayer, which maintains that Roundup is safe, is considering its options in the case and will continue to seek a Supreme Court review, it said.
‘Hiding Behind the EPA’
The case stems from a lawsuit filed by a consumer who used the popular weedkiller for decades and then developed cancer, alleging that Roundup caused his disease and claiming failure to warn of the product’s risks.
“Hiding behind the EPA is not valid,” Wisner said.
The case is John D. Carson v. Monsanto Co., 21-10994, 11th US Circuit Court of Appeals.
(Updates stock action in first section and adds Bloomberg Intelligence analysis in second.)
To contact the reporter on this story:
To contact the editors responsible for this story:
Marthe Fourcade, Peter Jeffrey
© 2024 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.